Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 17/20 | 0.76 |
| ▸ | CASP7 | P55210 | 13/20 | 0.76 |
| ▸ | CASP1 | P29466 | 7/20 | 0.76 |
| ▸ | CASP9 | P55211 | 5/20 | 0.76 |
| ▸ | CASP4 | P49662 | 3/20 | 0.59 |
| ▸ | CASP10 | Q92851 | 3/20 | 0.59 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.59 |
| ▸ | CASP5 | P51878 | 1/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28399571 | 0.95 | CASP3 (0.70) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL17326941 | 0.93 | CASP3 (0.72) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL31003038 | 0.93 | CASP3 (0.67) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL29732392 | 0.92 | CASP3 (0.71) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL20239336 | 0.92 | CASP3 (0.71) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL13823621 | 0.91 | CASP3 (0.65) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL30002726 | 0.90 | CASP3 (0.69) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL16770334 | 0.90 | CASP3 (0.68) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2744395 | 0.89 | CASP3 (0.68) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL28540771 | 0.89 | CASP3 (0.68) | CASP3CASP7CASP1CASP9CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163459-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC PHARMACEUTICALS GMBH (DE) | 2025-05-22 | — | — | US | claimed |
| EP-4486872-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC Pharmaceuticals GmbH (DE) | 2025-01-08 | — | — | EP | claimed |
| CN-118804973-A | Improved cell lines and methods for producing adeno-associated vectors | 塞维克制药有限责任公司 | 2024-10-18 | — | — | CN | claimed |
| US-20240272146-A1 | CHROMOGENIC AND FLUOROGENIC COMPOUNDS AND THEIR USE FOR BIOLOGICAL DETECTION | AAT BIOQUEST, INC. | 2024-08-15 | — | — | US | claimed |
| EP-3548470-B1 | 5,5-DISUBSTITUTED LUCIFERINS AND THEIR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2023-11-01 | — | — | EP | claimed |
| WO-2023166026-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC PHARMACEUTICALS GMBH (DE) | 2023-09-07 | — | — | WO | claimed |
| EP-4239063-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC Pharmaceuticals GmbH (DE) | 2023-09-06 | — | — | EP | claimed |
| CN-110545837-B | Use of pathways associated with autoinducers for inducing apoptosis and anti-infective therapy | 清华大学 | 2022-09-27 | — | — | CN | claimed |
| EP-3720480-B1 | PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS | JUNO THERAPEUTICS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122081213-A | Preparation method and application of enucleated mesenchymal stem cells for in-situ release of apoptotic bodies | — | 2026-05-26 | — | — | CN | disclosed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4719370-A1 | COMPOUNDS FOR USE IN ORGAN PRESERVATION AND ORGAN TRANSPLANTATION | Abrexa Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260076926-A1 | COMPOUNDS FOR USE IN ORGAN PRESERVATION AND ORGAN TRANSPLANTATION | ABREXA PHARMACEUTICALS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2026044087-A1 | INCREASED CELLULAR STABILITY FOR AAV PRODUCTION | SHAPE THERAPEUTICS INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| WO-2022056196-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PULMONARY HYPERTENSION | PULMOSIM THERAPEUTICS LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| CN-114177166-A | Treatment and diagnosis of colon cancer | 洛克菲勒大学 | 2022-03-15 | — | — | CN | disclosed |
| EP-3946437-A1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | Myst Therapeutics, LLC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-109793897-B | Treatment and diagnosis of colon cancer | 洛克菲勒大学 | 2022-02-01 | — | — | CN | disclosed |
| WO-2022016267-A1 | SENOTHERAPEUTIC DRUGS FOR AGE-RELATED DISEASES AND CANCER | HAGLUND LISBET AGNETA (CA) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076926-A1 | COMPOUNDS FOR USE IN ORGAN PRESERVATION AND ORGAN TRANSPLANTATION | CASP9, CASP3, CASP10 | CASP3 2/4885CASP7 7/4885CASP1 214/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | CASP3 3762/4885CASP7 3415/4885CASP1 3588/4885 |
| US-20240272146-A1 | CHROMOGENIC AND FLUOROGENIC COMPOUNDS AND THEIR USE FOR BIOLOGICAL DETECTION | ANTXR2, CDYL, VIP | CASP3 221/4885CASP7 354/4885CASP1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.